CSF2 and ovarian cancer: This trial has established the peptide dose for a larger scale, prospective, randomized, GM-CSF controlled trial using the E39 peptide vaccine to prevent recurrence after treatment for primary disease in HLA-A2 positive endometrial and ovarian cancer patients.